$16B Ring: Should Pricing Be Based on Hardware or Data?

A 4-gram metal ring, no screen, established for 13 years, selling 5.5 million units annually, planning to raise up to $3 billion, with a valuation exceeding $16 billion. Subscription revenue accounts for 20% of total sales, paid members approach 5 million, and ARR is approximately $144 million. Goldman Sachs, Morgan Stanley, and JPMorgan are all on the underwriting syndicate. After seeing these numbers, my first reaction was: what exactly is this valuation betting on?

My judgment is straightforward: the product has barriers, the valuation is aggressive, and lawsuits have brought the core evidence chain to the forefront. I wouldn’t chase it in the primary market; in the secondary market, I’d observe first. It looks more like a data subscription asset wearing a ring shell, neither like typical consumer electronics nor a mature medical company. The valuation anchor lies in subscriptions and the evidence chain.

Valuation Logic: Hardware Sells the Entry Point, Subscriptions Sell the Story

Oura’s path resembles early Fitbit: wearable hardware collects data, and software turns that data into health services. The difference is that it stacks AI and subscriptions together, leading the market to assign higher multiples.

Roughly calculating based on the provided figures, a $16 billion valuation against $144 million ARR puts the multiple over 100x. This multiple primarily pays for retention, repurchase, data networks, and future insurance/medical scenarios. Investors are betting that the millions willing to pay long-term can turn a ring into a personal health entry point.

But the business model fears one question most: Are people paying for features, or for conclusions?

The core argument in the lawsuit is sharp: Sleep happens in the brain, not the finger. The medical community recognizes polysomnography (PSG) as the gold standard for sleep staging, requiring professional signals like EEG, EOG, and muscle tension. Rings can only capture peripheral signals like heart rate, body temperature, and blood oxygen, then infer sleep stages via algorithms. If this inference is marketed only as a consumer-grade reference, it’s fine. But once advertised as reliable health facts, it becomes regulatory and litigation risk.

Recently, I’ve been looking at several AI hardware projects and also testing a code audit Agent I picked up less than a week ago. The idea is simple: the faster the generation speed, the more we need a trust layer before merging. Ring-based intimate data products are the same. Models can infer, but whether the inference process is replayable, how annotations are sourced, and whether users understand the boundaries—all affect pricing post-launch.

Technical Barriers: Engineering Chain Matters More

Many people look at smart rings and first mention imperceptible wear, design, and sensors. These are important but don’t necessarily constitute high barriers. Apple and Samsung are both entering the fray. Once supply chains mature, hardware forms will quickly level out.

How high are the technical barriers? I focus on four layers. Engineering ranks first: fitting batteries, antennas, chips, and sensors into a millimeter-scale ring space, while withstanding water ingress, drops, and long-term skin contact. In 2025, the Galaxy Ring experienced battery swelling issues preventing removal; such risks turn "imperceptible" into "high-risk."

The data chain depends on whether users wear it, whether data is accurate, and whether algorithms can calibrate for individual differences. These determine subscription renewal rates. The product begins after the ring is sold.

Clinical evidence is harder. To enter health, you must face hospitals, insurers, regulators, and real-world data. Between consumer-grade algorithms and medical-grade conclusions lies a whole validation process.

Team execution is also key. Hard tech fears beautiful demos and poor mass production.

Oura selling 5.5 million units indicates success in supply chain and channels. Whether it can deepen post-IPO depends on whether the team can convert marketing growth into evidence growth.

I’ve used digital pathology images for two weeks, and a deep takeaway is that no matter how well a model identifies patterns, the prerequisite is that data is annotatable, reviewable, and accountable. The same applies to sleep data collected by rings. The closer it gets to health facts, the more it needs an auditable evidence chain. Otherwise, a $16 billion valuation will be knocked back to consumer accessory status by a lawsuit.

Exit Path: IPO is a Pricing Test

From a PE perspective, the exit path is crucial. Oura plans to raise up to $3 billion, with some existing shareholders also selling shares. Early investors hoping to cash out at a $16 billion valuation is normal. A strong underwriting syndicate suggests liquidity expectations aren’t bad.

But an IPO is more like a pricing test in the public market. Three test questions: Can subscription retention withstand slowing hardware growth? Will lawsuits change marketing claims? With Apple and Samsung entering, will users be sucked away by ecosystems?

If Oura is just a high-end wearable, the valuation is hard to sustain long-term. If it can prove itself as a personal health data platform—with APIs, insurance, medical partnerships, and device licensing—the story can go another round.

My conclusion is that this ring is worth studying, but it’s not suitable to increase positions just because of celebrity hype and AI labels. How high the technical barriers are depends on whether they can be audited. Hardware barriers will be ground down by supply chains; algorithm barriers will be copied by giants. Long-term, compliant, and verifiable data chains are scarcer.

Looking ahead, I’ll actually watch more specific metrics: subscription renewal rates, number of clinical collaborations, lawsuit progress, and user migration to/from Apple/Samsung rings. Once this data emerges, I’ll decide whether to treat it as a consumer brand, a data company, or a high-risk AI hardware target.

After listing, whether the evidence chain can be audited is the key.